In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome

IVF/ICSI Outcomes of OCP Plus GnRH Agonist Protocol Versus OCP Plus GnRH Antagonist Fixed Protocol in Women With PCOS

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01354275

Acronym

PCOS and ivf

Enrollment

300

Registered

2011-05-16

Start date

2009-03-31

Completion date

2011-06-30

Last updated

2012-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCOS GnRH Antagonist and GnRH Agonist IVF/ICSI Cycles

Keywords

PCOS, IVF/ICSI, Clinical Pregnancy rates, GnRH Antagonist, GnRH Agonist

Brief summary

Outcomes of IVF/ICSI cycles of women with PCOS undergoing Gonadotropin Releasing Hormone (GnRH) agonist and GnRH Antagonist fixed protocol.

Detailed description

Women with PCOS undergoing IVF/ICSI cycles will be evaluated by two different protocols. One arm of the study includes oral contraceptive plus GnRH agonist protocol with 150 IU FSH (standard dose) and second arm includes oral contraceptive plus GnRH Antagonist with 150 IU FSH dose and fixed 6th day starting of GnRH Antagonist.

Interventions

OTHERTo compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle

150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle

OTHERGnRH Antagonist

GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* PCOS women undergoing ICSI cycles * All women will be administered 150 IU rec FSH

Exclusion criteria

* Women having other endocrinopathies * women older than 35 * third IVF/ICSI cycles * previous and current use of metformin

Design outcomes

Primary

Measure	Time frame	Description
Ongoing pregnancy rates	March 2009 to June 2011	Ongoing pregnancy rates measured in OCP plus GnRH Agonist and OCP plus GnRH Antagonist cycles in women with PCOS
clinical pregnancy rate	from march 2009 to july 2011	To evaluate the clinical pregnancy rates of both study arms
Total gonadotropin use	From march 2009 to June 2011	Total gonadotropin use of both study arms

Secondary

Measure	Time frame	Description
OHSS rates	from march 2009 to july 2011	OHSS rates in both study groups
Total ongoing pregnancy rate	from march 2009 to june 2011	Total ongoing pregnacy rates of per protocol group including freezing-thawing embryo transfer cycles.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026